Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults



Status:Completed
Conditions:HIV / AIDS, Hepatitis, Hepatitis
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - Any
Updated:11/18/2018
Start Date:February 25, 2014
End Date:October 26, 2016

Use our guide to learn which trials are right for you!

A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults

This study will assess the efficacy, safety, and tolerability of
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose
combination (FDC) in human immunodeficiency virus (HIV)/hepatitis B virus (HBV) coinfected
adults.

Participants will be enrolled into two cohorts:

- Cohort 1: HIV/HBV coinfected adults who are HIV treatment-naive and HBV treatment-naive

- Cohort 2: HIV/HBV coinfected adults who are HIV-suppressed


Key Inclusion Criteria:

- Both Cohorts 1 and 2:

- The ability to understand and sign a written informed consent form, which must be
obtained prior to initiation of study procedures

- HIV/HBV co-infected adult males and non-pregnant and non-lactating females

- No evidence of hepatocellular carcinoma (HCC) or clinical or imaging evidence of
cirrhosis (ascites, variceal bleeding, encephalopathy).

--- Subjects should have documentation of an abdominal ultrasound in the 12
months prior to screening, or an abdominal ultrasound at screening, demonstrating
the absence of cirrhosis and HCC.

- Acute Hepatitis A virus (HAV) immunoglobulin M (IgM) negative

- Hepatitis C virus (HCV) Ab negative, or HCV Ab positive with negative HCV RNA

- Hepatitis D virus (HDV) Ab negative, or HDV Ab positive with negative HDV RNA

- Estimated glomerular filtration rate (eGFR) ≥ 50 mL/min according to the
Cockcroft-Gault formula

- CD4+ count of > 200 cells/μL

- Chronic HBV infection as defined by

- HBsAg positive for ≥ 6 months Or

- HBsAg positive at screening and either hepatitis B e antigen (HBeAg) or HBV
DNA positive ≥ 6 months Or

- At screening: positive total hepatitis B core antibody (HBcAb) and negative
immunoglobulin M antibody to hepatitis B core antigen (HBcIgM) antibody, and

- HBsAg positive, or

- HBeAg positive, or

- HBV DNA positive

- Cohort 1 (HIV and HBV treatment naive) only:

- No current or prior anti-HIV treatment, including antiretroviral medications
received for prevention (PrEP), or post exposure prophylaxis (PEP)

- No current or prior anti-HBV treatment

- Plasma HIV-1 RNA level ≥ 500 copies/mL at screening

- Screening HBV DNA ≥ 3 log10 IU/mL and < 9 log10 IU/mL

- Cohort 2 (HIV suppressed) only:

- Receiving current antiretroviral regimen for at least 4 consecutive months

- No current or prior regimen containing 3 active anti-HBV agents (i.e. cannot be
on tenofovir alafenamide (TDF)/emtricitabine (FTC)/Entecavir or
TDF/lamivudine(3TC)/Entecavir)

- Maintained plasma HIV-1 RNA < 50 copies/mL for 6 consecutive months prior to and
at the time of the screening visit. Unconfirmed virologic evaluation of ≥ 50
copies/mL after previously reaching viral suppression (transient detectable
viremia, or "blip") and prior to screening is acceptable

- Documented positive HIV antibody test

- Screening HBV DNA < 9 log10 IU/mL

Key Exclusion Criteria:

- Females who are breastfeeding

- Positive serum pregnancy test (female of childbearing potential)

- Have an implanted defibrillator or pacemaker

- Current alcohol or substance use

- A history of malignancy within the past 5 years (prior to screening) or ongoing
malignancy other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or
resected, non-invasive carcinoma.

- Received solid organ or bone marrow transplant

- Any history of, or current evidence of, clinical hepatic decompensation (e.g.,
ascites, encephalopathy or variceal hemorrhage).

- Significant bone disease (e.g., osteomalacia, chronic osteomyelitis, osteogenesis
imperfecta, osteochondroses), or multiple bone fractures

- Active, serious infections (other than HIV-1 infection) requiring parenteral
antibiotic or antifungal therapy within 30 days prior to Day 1

- Subjects on hemodialysis, other forms of renal replacement therapy, or on treatment
for underlying kidney diseases (including prednisolone, and dexamethasone)

- Any other clinical condition or prior therapy that, in the opinion of the
Investigator, would make the subject unsuitable for the study or unable to comply with
the dosing requirements

- Investigational agents (unless approved by Gilead Sciences). Participation in any
other clinical trial without prior approval from the sponsor is prohibited while
participating in this trial

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
We found this trial at
22
sites
Washington, District of Columbia 20009
?
mi
from
Washington,
Click here to add this to my saved trials
900 East 30th Street
Austin, Texas 78705
512-480-9660
?
mi
from
Austin, TX
Click here to add this to my saved trials
Bellaire, Texas 77401
?
mi
from
Bellaire, TX
Click here to add this to my saved trials
Berkley, Michigan 48072
?
mi
from
Berkley, MI
Click here to add this to my saved trials
Beverly Hills, California 90211
?
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Clearwater, Florida 33765
?
mi
from
Clearwater, FL
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Fort Lauderdale, Florida 33316
?
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Fort Pierce, Florida 34982
?
mi
from
Fort Pierce, FL
Click here to add this to my saved trials
Houston, Texas 77098
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas 77004
?
mi
from
Houston, TX
Click here to add this to my saved trials
Kansas City, Missouri 64111
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
Los Angeles, California 90036
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Los Angeles, California 90069
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Miami Beach, Florida 33139
?
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Phoenix, Arizona 85012
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Saint Louis, Missouri 63139
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Santa Fe, New Mexico 87505
?
mi
from
Santa Fe, NM
Click here to add this to my saved trials
Seattle, Washington 98104
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
Toronto,
Click here to add this to my saved trials
?
mi
from
Vero Beach, FL
Click here to add this to my saved trials
West Palm Beach, Florida 33401
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials